PACB - Pacific Biosciences of California Non-GAAP EPS of -$0.32 beats by $0.01 revenue of $32.31M misses by $3.09M

• Pacific Biosciences of California press release ( NASDAQ: PACB ): Q3 Non-GAAP EPS of -$0.32 beats by $0.01 .
• Revenue of $32.31M (-7.4% Y/Y) misses by $3.09M .
• Instrument revenue of $11.4 million, compared with $15.9 million in the prior year period.
• Consumables revenue of $16.1 million compared with $14.6 million in the prior year period.
• Service and other revenue of $4.8 million, compared with $4.4 million in the prior year period.
• Delivered 34 Sequel IIe systems, compared with 44 Sequel II/IIe systems in the prior year period.
• Installed base of 494 Sequel II/IIe systems as of September 30, 2022, compared with 326 as of September 30, 2021.

For further details see: